Presentation is loading. Please wait.

Presentation is loading. Please wait.

Volume 51, Issue 4, Pages (April 2007)

Similar presentations


Presentation on theme: "Volume 51, Issue 4, Pages (April 2007)"— Presentation transcript:

1 Volume 51, Issue 4, Pages 962-970 (April 2007)
A Chemosensitivity Test for Superficial Bladder Cancer Based on Three-Dimensional Culture of Tumour Spheroids  Juan Pablo Burgués, Luis Gómez, José Luis Pontones, César David Vera, Juan Fernando Jiménez-Cruz, Mariano Ozonas  European Urology  Volume 51, Issue 4, Pages (April 2007) DOI: /j.eururo Copyright © 2006 European Association of Urology Terms and Conditions

2 Fig. 1 (A) Spheroid on the seventh day of culture at 200 augmentations (hematoxylin-eosin stain). (B) Spheroids as seen with the use of an inverted microscope at 40 augmentations. European Urology  , DOI: ( /j.eururo ) Copyright © 2006 European Association of Urology Terms and Conditions

3 Fig. 2 Mean growth curves of spheroids from 11 tumours. The growth is expressed as the percentage of initial mean orthogonal diameter along days of culture. European Urology  , DOI: ( /j.eururo ) Copyright © 2006 European Association of Urology Terms and Conditions

4 Fig. 3 (A) Masson tricromic staining (200 augmentations): epithelial cells are stained in blue and collagen in green. (B) Collagen IV immunostaining (200 augmentations): basal membranes around stromal capillaries and below urothelium are stained. (C) Cytokeratin 7 immunostaining (200 augmentations): specific for glandular and urothelial cells. (D) Vimentin immunostaining (200 augmentations): specific for mesenchymal cells such as fibroblasts, vascular endothelial cells, macrophages, and haematopoietic cells. European Urology  , DOI: ( /j.eururo ) Copyright © 2006 European Association of Urology Terms and Conditions

5 Fig. 4 (A) Sensitivity profile in patient 18 (p<0.001). (B) Sensitivity profile in patient 29 (p=0.027). European Urology  , DOI: ( /j.eururo ) Copyright © 2006 European Association of Urology Terms and Conditions

6 Fig. 5 Mean sensitivities to EPI+VPM, EPI, ADR, THIO, and MMC in the 31 evaluable patients. Altogether, differences were statistically significant (p<0.001). Post hoc pair-wise multiple comparisons were all significant except for EPI versus ADR (p=1). ADR: adriamycin; CIPRO: ciprofloxacin; EPI: epirubicin; MMC: mitomycin C; THIO: thiotepa; VPM: verapamil. European Urology  , DOI: ( /j.eururo ) Copyright © 2006 European Association of Urology Terms and Conditions

7 Fig. 6 Cell viability after exposure to 0.2mg/ml CIPRO for 72h alone or in combination with EPI compared with EPI alone and the control (p>0.05) in the first 22 patients. CIPRO: ciprofloxacin; EPI: epirubicin. European Urology  , DOI: ( /j.eururo ) Copyright © 2006 European Association of Urology Terms and Conditions


Download ppt "Volume 51, Issue 4, Pages (April 2007)"

Similar presentations


Ads by Google